Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical
Executive Summary
Sequana Medical is simultaneously developing both drug and device treatments for fluid overloads in the body. Medtech Insight spoke to the company’s CEO about their trials and the challenges of raising cash in 2023.
You may also be interested in...
Cordio Medical Is Using Patients’ Voices To Spot Heart Failure
As fluid builds up in the lungs, the “engine” of a patient’s voice is smothered. Medtech Insight spoke to Cordio Medical’s CEO about how the company’s smartphone-based software could warn clinicians almost three weeks in advance of decompensation.
Exec Chat: Sequana Medical Pursues Dual Device-Drug Strategy For Fluid Overload
Speaking to Medtech Insight, Sequana Medical’s CEO discussed the company’s two technologies for combating fluid overload whilst explaining that, sometimes, chasing approval as a drug can be the best way to ensure easy market access.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.